KR102708864B1 - 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 - Google Patents

글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 Download PDF

Info

Publication number
KR102708864B1
KR102708864B1 KR1020237014250A KR20237014250A KR102708864B1 KR 102708864 B1 KR102708864 B1 KR 102708864B1 KR 1020237014250 A KR1020237014250 A KR 1020237014250A KR 20237014250 A KR20237014250 A KR 20237014250A KR 102708864 B1 KR102708864 B1 KR 102708864B1
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
insulin
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237014250A
Other languages
English (en)
Korean (ko)
Other versions
KR20230062673A (ko
Inventor
제스퍼 그로마다
하루카 오카모토
스티븐 제스퍼스
조이스 하프
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59799505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102708864(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020247021936A priority Critical patent/KR20240110661A/ko
Publication of KR20230062673A publication Critical patent/KR20230062673A/ko
Application granted granted Critical
Publication of KR102708864B1 publication Critical patent/KR102708864B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237014250A 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 Active KR102708864B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247021936A KR20240110661A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662381263P 2016-08-30 2016-08-30
US62/381,263 2016-08-30
US201662411032P 2016-10-21 2016-10-21
US62/411,032 2016-10-21
PCT/US2017/049137 WO2018044903A1 (en) 2016-08-30 2017-08-29 Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
KR1020197008021A KR20190044079A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008021A Division KR20190044079A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247021936A Division KR20240110661A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법

Publications (2)

Publication Number Publication Date
KR20230062673A KR20230062673A (ko) 2023-05-09
KR102708864B1 true KR102708864B1 (ko) 2024-09-25

Family

ID=59799505

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197008021A Ceased KR20190044079A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
KR1020247021936A Ceased KR20240110661A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
KR1020237014250A Active KR102708864B1 (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020197008021A Ceased KR20190044079A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
KR1020247021936A Ceased KR20240110661A (ko) 2016-08-30 2017-08-29 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법

Country Status (12)

Country Link
US (3) US10995146B2 (enExample)
EP (1) EP3506940A1 (enExample)
JP (3) JP7173962B2 (enExample)
KR (3) KR20190044079A (enExample)
CN (2) CN118236497A (enExample)
AU (2) AU2017321423C1 (enExample)
CA (1) CA3034777A1 (enExample)
IL (1) IL322691A (enExample)
MA (1) MA46089A (enExample)
MX (2) MX385598B (enExample)
SG (2) SG10201913074WA (enExample)
WO (1) WO2018044903A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7173962B2 (ja) 2016-08-30 2022-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3914711A2 (en) * 2019-01-23 2021-12-01 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
WO2021045515A1 (ko) 2019-09-04 2021-03-11 (주)에이파마 아이티아이에이치원의 내당능장애를 수반하는 질환의 인슐린 저항성 검출용 바이오마커로서의 용도
CN113481290B (zh) * 2021-06-30 2022-08-23 华南农业大学 一种klf4基因在制备检测和/或减少母鼠不良妊娠结局的产品中的应用
CN114342875A (zh) * 2022-01-12 2022-04-15 吉林大学 一种新型妊娠糖尿病动物模型的建立方法
WO2025042188A1 (ko) 2023-08-21 2025-02-27 주식회사 엘지에너지솔루션 셀 어셈블리 및 이를 포함하는 전지 모듈, 그리고 셀 어셈블리 제조방법

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (ja) 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
JPS56163456A (en) 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
HU219674B (hu) 1992-08-28 2001-06-28 Novo Nordisk A/S Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra
JP2729159B2 (ja) 1994-10-31 1998-03-18 日清製粉株式会社 ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP2007514794A (ja) 2003-12-19 2007-06-07 メルク　エンド　カムパニー　インコーポレーテッド 環式グアニジン、そのような化合物を含む組成、及び使用方法
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
CN1964947A (zh) 2004-06-04 2007-05-16 默克公司 吡唑衍生物、包含其的组合物及其用法
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
JP2008507528A (ja) 2004-07-22 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 置換ピラゾール、このような化合物を含有する組成物及び使用方法
US8084489B2 (en) 2005-02-11 2011-12-27 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
EP2015776A1 (en) 2006-04-20 2009-01-21 Amgen Inc. Glp-1 compound/glucagon antibody compositions
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
DK2129654T3 (da) 2007-02-09 2014-08-25 Metabasis Therapeutics Inc Antagonister af glucagonreceptoren
PE20091674A1 (es) 2008-03-27 2009-11-04 Lilly Co Eli Antagonistas del receptor de glucagon
JP2011520897A (ja) 2008-05-16 2011-07-21 シェーリング コーポレイション グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法
EP2346830B1 (en) 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010071750A1 (en) 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
WO2010088061A1 (en) 2009-01-28 2010-08-05 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098948A1 (en) 2009-02-13 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use
WO2010098994A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP2758533B1 (en) 2011-09-20 2018-04-11 Ionis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
JP2015505828A (ja) 2011-12-02 2015-02-26 イーライ リリー アンド カンパニー 抗グルカゴン抗体およびその使用
SG11201508264UA (en) 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
JP2017533695A (ja) * 2014-09-16 2017-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗グルカゴン抗体およびその使用
JP7173962B2 (ja) 2016-08-30 2022-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法

Also Published As

Publication number Publication date
KR20230062673A (ko) 2023-05-09
MX2019002437A (es) 2019-10-09
SG11201901355SA (en) 2019-03-28
US20210221896A1 (en) 2021-07-22
US10995146B2 (en) 2021-05-04
MA46089A (fr) 2019-07-10
SG10201913074WA (en) 2020-03-30
IL322691A (en) 2025-10-01
AU2017321423B2 (en) 2024-09-26
RU2019107807A3 (enExample) 2021-05-18
AU2024278594A1 (en) 2025-01-30
JP7633213B2 (ja) 2025-02-19
JP2022140605A (ja) 2022-09-26
AU2017321423C1 (en) 2025-01-30
JP2019528306A (ja) 2019-10-10
KR20240110661A (ko) 2024-07-15
CN109922831A (zh) 2019-06-21
US11708416B2 (en) 2023-07-25
JP2024178249A (ja) 2024-12-24
RU2019107807A (ru) 2020-10-01
US20230416384A1 (en) 2023-12-28
CN118236497A (zh) 2024-06-25
EP3506940A1 (en) 2019-07-10
MX2021006457A (es) 2021-07-02
CA3034777A1 (en) 2018-03-08
AU2017321423A1 (en) 2019-03-14
MX385598B (es) 2025-03-18
US20190218301A1 (en) 2019-07-18
KR20190044079A (ko) 2019-04-29
JP7173962B2 (ja) 2022-11-16
WO2018044903A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US12269889B2 (en) Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels
KR102708864B1 (ko) 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
AU2020277207B2 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
KR102440044B1 (ko) 항-액티빈 a 항체 및 그의 용도
KR101842570B1 (ko) 사람 안지오포이에틴-유사 단백질 4에 대한 사람 항체
KR20170062466A (ko) 항-글루카곤 항체 및 그것의 사용
AU2016307430A1 (en) Anti-ANGPTL8 antibodies and uses thereof
CN111789944A (zh) 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
US20230322907A1 (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
PH12014501730B1 (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
US20250101119A1 (en) Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
RU2772508C2 (ru) Способы лечения тяжелой инсулинорезистентности путем прерывания передачи сигнала глюкагонового рецептора
HK1190159A (en) Human antibodies to the glucagon receptor
HK1190159B (en) Human antibodies to the glucagon receptor

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230426

Application number text: 1020197008021

Filing date: 20190320

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20230509

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230607

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230607

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20240701

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240829

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240919

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240920

End annual number: 3

Start annual number: 1

PG1601 Publication of registration